A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients
Open Access
- 25 June 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Psychiatry
- Vol. 7 (1), 28
- https://doi.org/10.1186/1471-244x-7-28
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baselineSchizophrenia Research, 2006
- Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemiaJournal of Psychopharmacology, 2006
- Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes FederationDiabetic Medicine, 2006
- Schizophrenia: who is at risk? Who is a case?International Clinical Psychopharmacology, 2006
- Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?Journal of Psychopharmacology, 2005
- Effectiveness of Antipsychotic Drugs in Patients with Chronic SchizophreniaThe New England Journal of Medicine, 2005
- Testing for diabetes in hospitalised patients prescribed antipsychotic drugsThe British Journal of Psychiatry, 2004
- Consensus Statement: Consensus Development Conference on Antipsychotic Drugs and Obesity and DiabetesBritish Journal of Psychology, 2004
- Excess mortality of schizophreniaThe British Journal of Psychiatry, 1997
- FAMILY HISTORY OF TYPE 2 DIABETES IN SCHIZOPHRENIC PATIENTSThe Lancet, 1989